OINDPnews


Copley Scientific banner

News

Milestone raises $17 million for Phase 2 development of intranasal calcium channel antagonist

Milestone Pharmaceuticals has raised $17 million in a Series B financing round, the company said. According to the company, it will use the money for Phase 2 clinical development of MSP-2017, its intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). In November 2014, Milestone announced positive Phase 1 results … [Read more...] about Milestone raises $17 million for Phase 2 development of intranasal calcium channel antagonist

AmpliPhi study demonstrates viability of bacteriophages after nebulization

AmpliPhi BioSciences has announced that a study performed in conjunction with the Royal Brompton Hospital and Imperial College, UK showed that a variety of bacteriophages remain viable against P. aeruginosa after nebulization. Three different commercially available nebulizers were used to test four different bacteriophages. Earlier this year, AmpliPhi announced … [Read more...] about AmpliPhi study demonstrates viability of bacteriophages after nebulization

VARI partners with Nativa on MDIs

Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two companies signed an agreement at CPhI Russia 2015, which took place in April. According to the company's web site, Nativa … [Read more...] about VARI partners with Nativa on MDIs

Mylan launches Sirdupla salmeterol/fluticasone MDI in the UK

Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline's Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in 125/25 mcg and 250/25 mcg versions, is manufactured by 3M Drug Delivery Systems. Mylan President Rajiv Malik … [Read more...] about Mylan launches Sirdupla salmeterol/fluticasone MDI in the UK

Adapt Pharma initiates rolling NDA submission for intranasal naloxone

Adapt Pharma has initiated a rolling NDA submission for intranasal naloxone for the treatment of opioid overdose, the company said. Adapt licensed the intranasal naloxone formulation from Lightlake Therapeutics in December 2014 and received Fast Track Designation for the product from the FDA in February 2015. Lightlake CEO Roger Crystal said, "This is a very … [Read more...] about Adapt Pharma initiates rolling NDA submission for intranasal naloxone

Turing Pharmaceuticals hires Eliseo Salinas as President of R&D

Turing Pharmaceuticals, which is developing intranasal oxytocin and ketamine products, has announced that it has hired Eliseo Oreste Salinas as President of Research and Development. Salinas was most recently President and Chief Scientific Officer of Relmada Therapeutics. According to the company, "He arrives as Turing prepares to begin clinical trials for several … [Read more...] about Turing Pharmaceuticals hires Eliseo Salinas as President of R&D

Pulmotect gets $3 million grant for development of inhaled therapy for respiratory infections in cancer patients

The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory infections in cancer patients whose immune systems have been compromised, the company has announced. In 2012, Pulmotect received a a $7.1 million … [Read more...] about Pulmotect gets $3 million grant for development of inhaled therapy for respiratory infections in cancer patients